Serum Vitamin D Status and Breast Cancer Risk by Receptor Status: A Systematic Review

References

• DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, et al.: Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 66, 31–42, 2016. doi:10.3322/caac.21320.
   PubMed Web of Science ®Google Scholar
• Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, et al.: Therapeutic targets of triple-negative breast cancer: A review. Br J Pharmacol 172, 4228–4237, 2015. doi:10.1111/bph.13211.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, et al.: Strategies for subtypes–dealing with the diversity of breast cancer: Highlights of the st. gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22, 1736–1747, 2011. doi:10.1093/annonc/mdr304.
   PubMed Web of Science ®Google Scholar
• Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, et al.: Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2), S26–35, 2015. doi:10.1016/j.breast.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Dai X, Li T, Bai Z, Yang Y, Liu X, et al.: Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5, 2929–2943, 2015.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, et al.: Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20, 474–482, 2015. doi:10.1634/theoncologist.2014-0372.
   PubMed Web of Science ®Google Scholar
• Linus Pauling Institute: Vitamin D. 2014.
   Google Scholar
• Enko D, Fridrich L, Rezanka E, Stolba R, Ernst J, et al.: 25-hydroxy-vitamin D status: Limitations in comparison and clinical interpretation of serum-levels across different assay methods. Clin Lab 60, 1541–1550, 2014. doi:10.7754/Clin.Lab.2014.131114.
   PubMed Web of Science ®Google Scholar
• Lopes N, Paredes J, Costa JL, Ylstra B, Schmitt F: Vitamin D and the mammary gland: A review on its role in normal development and breast cancer. Breast Cancer Res 14, 211, 2012. doi:10.1186/bcr3178.
   PubMed Web of Science ®Google Scholar
• So JY, Suh N: Targeting cancer stem cells in solid tumors by vitamin D. J Steroid Biochem Mol Biol 148, 79–85, 2015. doi:10.1016/j.jsbmb.2014.10.007.
   PubMed Web of Science ®Google Scholar
• Wang D, Velez de-la-Paz OI, Zhai JX, Liu DW: Serum 25-hydroxyvitamin D and breast cancer risk: A meta-analysis of prospective studies. Tumour Biol 34, 3509–3517, 2013. doi:10.1007/s13277-013-0929-2.
   PubMed Web of Science ®Google Scholar
• Kim Y, Je Y: Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: A meta-analysis. Br J Cancer 110, 2772–2784, 2014. doi:10.1038/bjc.2014.175.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 6, e1000100, 2009. doi:10.1371/journal.pmed.1000100.
   PubMed Web of Science ®Google Scholar
• Janssen MJ, Wielders JP, Bekker CC, Boesten LS, Buijs MM, et al.: Multicenter comparison study of current methods to measure 25-hydroxyvitamin D in serum. Steroids 77, 1366–1372, 2012. doi:10.1016/j.steroids.2012.07.013.
   PubMed Web of Science ®Google Scholar
• Peairs KS, Choi Y, Stewart RW, Sateia HF: Screening for breast cancer. Semin Oncol 44, 60–72, 2017. doi:10.1053/j.seminoncol.2017.02.004.
   PubMed Web of Science ®Google Scholar
• Abbas S, Chang-Claude J, Linseisen J: Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a german case-control study. Int J Cancer 124, 250–255, 2009. doi:10.1002/ijc.23904.
   PubMed Web of Science ®Google Scholar
• Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, et al.: Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res 2, 598–604, 2009. doi:10.1158/1940-6207.CAPR-08-0138.
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, et al.: Plasma 25-hydroxyvitamin D and risk of breast cancer in the nurses' health study II. Breast Cancer Res 13, 2011. doi:10.1186/bcr2880.
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Warner ET, Rosner B, Collins LC, Beck AH, et al.: Plasma 25-hydroxyvitamin D and risk of breast cancer in women followed over 20 years. Cancer Res 76, 5423–5430, 2016. doi:10.1158/0008-5472.CAN-16-0353.
   PubMed Web of Science ®Google Scholar
• Kuhn T, Kaaks R, Becker S, Eomois PP, Clavel-Chapelon F, et al.: Plasma 25-hydroxyvitamin D and the risk of breast cancer in the european prospective investigation into cancer and nutrition: A nested case-control study. Int J Cancer 133, 1689–1700, 2013. doi:10.1002/ijc.28172.
   PubMed Web of Science ®Google Scholar
• McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, et al.: Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: A nested case control study in the cancer prevention study-II nutrition cohort. Breast Cancer Res 11, 2009. doi:10.1186/bcr2356.
   PubMed Web of Science ®Google Scholar
• Park S, Lee DH, Jeon JY, Ryu J, Kim S, et al.: Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among korean women: A case-control study. Breast Cancer Res Treat 152, 147–154, 2015. doi:10.1007/s10549-015-3433-0.
   PubMed Web of Science ®Google Scholar
• Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, Skinner KA: The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol 19, 2590–2599, 2012. doi:10.1245/s10434-012-2297-3.
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, et al.: Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: A nested case-control study. Cancer Epidemiol Biomarkers Prev 18, 2655–2660, 2009. doi:10.1158/1055-9965.EPI-09-0531.
   PubMed Web of Science ®Google Scholar
• Scarmo S, Afanasyeva Y, Lenner P, Koenig KL, Horst RL, et al.: Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case-control study. Breast Cancer Res 15, R15, 2013. doi:10.1186/bcr3390.
   PubMed Web of Science ®Google Scholar
• Shirazi L, Almquist M, Borgquist S, Malm J, Manjer J: Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: A nested case-control study. Breast 28, 184–190, 2016. doi:10.1016/j.breast.2016.06.002.
   PubMed Web of Science ®Google Scholar
• Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, et al.: Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study. PLoS One 6, e17251, 2011. doi:10.1371/journal.pone.0017251.
   PubMed Web of Science ®Google Scholar
• Yao S, Hong C-, Mccann SE, Zirpoli G, Quan L, et al.: Combined effects of circulating levels of 25-hydroxyvitamin D and Th1 and Th2 cytokines on breast cancer estrogen receptor status. Cancers 6, 211–225, 2014. doi:10.3390/cancers6010211.
   PubMed Web of Science ®Google Scholar
• Abulkhair O, Saadeddin A, Makram O, Gasmelseed A, Pasha T, et al.: Vitamin D levels and breast cancer characteristics: Findings in patients from saudi arabia. J Steroid Biochem Mol Biol 164, 106–109, 2016. doi:10.1016/j.jsbmb.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Vitamin D Council: Testing for vitamin D. 2017.
   Google Scholar
• Forrest KY, Stuhldreher WL: Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res 31, 48–54, 2011. doi:10.1016/j.nutres.2010.12.001.
   PubMed Web of Science ®Google Scholar
• Lensmeyer G, Poquette M, Wiebe D, Binkley N: The C-3 epimer of 25-hydroxyvitamin D(3) is present in adult serum. J Clin Endocrinol Metab 97, 163–168, 2012. doi:10.1210/jc.2011-0584.
   PubMed Web of Science ®Google Scholar